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Abstract
Outcome reporting bias (ORB) occurs when outcomes in research
studies are selectively reported, the selection being influenced by the
study results. For benefit outcomes, Copas et al. (Biostatistics 2014)
shows how risk assessments using the ORBIT risk classification scale
can be used to calculate bias-adjusted treatment effect estimates. This
paper presents a new and simpler version of the benefits method, and
shows how it can be extended to cover the partial reporting and non-
reporting of harm outcomes. Our motivating example is a Cochrane
systematic review of 12 studies of Topiramate add-on therapy for drug-
resistant partial epilepsy (Pulman et al. 2014). Bias adjustments for
partially reported or unreported outcomes suggest that the review has
overestimated the benefits and underestimated the harms of the test
treatment.
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1 Introduction
Systematic reviews of clinical trials aim to include all relevant studies con-
ducted on a particular topic and to provide an unbiased summary of their
results, producing the best evidence on the benefits and harms of medical
treatments. Recommendations made by the National Institute for Health
and Clinical Excellence (NICE), who issue guidance on the use of treatments
and procedures within the NHS, are based largely on systematic reviews [1].
Outcome reporting bias (ORB) has been defined as the selection, on the ba-
sis of the results, of a subset of the original outcomes recorded for inclusion
in publication of trials [2]. A recent updated review of empirical research
provides strong evidence that outcomes that are statistically significant have
higher odds of being fully reported (range of odds ratios: 2.2 to 4.7) [3].
Much of the work to date on ORB has been limited in relation to evidence
surrounding reporting bias for benefit outcomes with little attention being
paid to harm outcomes. Important harm outcomes may also be subject to
outcome reporting bias when trialists prefer to focus on the positive bene-
fits of an experimental intervention [4]. In other words, for harm outcomes,
bias may occur if specific harms had been reported, but the data were pre-
sented or suppressed in a way that would mask the harm profile of particular
interventions.
The ORBIT (Outcome Reporting Bias in Trials) study described the
prevalence and impact of outcome reporting bias in systematic reviews for
benefit outcomes [5], while the more recent ORBIT II study has assessed
whether selective reporting is likely to have occurred in harm outcomes [4].
Across the two ORBIT studies, a nine point classification system (repro-
duced here as Table 1) was developed to assess the risk of ORB within study
reports for benefit outcomes while a complementary 13 point classification
system (reproduced here as Table 2) was developed to assess the risk in harm
outcomes.
In the presence of outcome reporting bias within a review, sensitivity
analyses have been proposed to assess the impact of outcome reporting bias
on an individual review [6]. However, these methods are limited to benefit
outcomes, where bias can arise if outcomes which are measured but fail to
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show a significant treatment effect are less likely to be reported. In this article
we show how the model-based sensitivity approach in [6] can be adapted to
adjust for ORB in harm outcomes where the resultant bias may not be related
to the significance of the outcome data. We apply our method to a Cochrane
systematic review of Topiramate add-on therapy for drug-resistant partial
epilepsy.
2 Motivating example
Missing outcome data
The Cochrane systematic review Topiramate add-on for drug-resistant
partial epilepsy [7] evaluates the efficacy and tolerability of topiramate when
used as an add-on treatment for people with drug resistant partial epilepsy.
The review considered two benefit outcomes and 12 harm outcomes. There
were 11 studies included in the review, whilst one study was excluded due
to there being no relevant outcome data. All 12 studies were considered
in this assessment. The outcome matrix in Table 3 shows which outcomes
were reported for each trial, and which outcomes were missing or partially
reported. Outcomes are considered to be fully reported if sufficient infor-
mation is provided such that the outcome could be included in the review
meta analysis. Partially reported outcomes are those that are inadequately
reported for inclusion in the review meta analysis (for example, an effect size
was presented with no measure of precision or exact p-value). From the out-
come matrix it is clear that the primary benefit outcome (50% reduction in
seizure frequency) and harm outcome (treatment withdrawal) were reported
in all included studies. In the excluded study these outcomes may have
been measured but not reported. The other main benefit outcome (seizure
freedom) was only reported in five of the eligible studies. Of the remaining
eleven harm outcomes, the number of studies reporting data ranged from
three (speech difficulty) to nine (fatigue).
Outcome reporting bias assessment
Three of the authors (JJK, AM, PRW - two statisticians and one clini-
cian with expertise in neurology) gave a classification independently for each
eligible study that did not report or partially reported on the review benefit
and harm outcomes in accordance with the classification system presented in
Tables 1 and 2. The agreed classifications are included in the outcome matrix
(Table 3). Justifications for each of the classifications can be found in Sup-
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plementary Table 2. In summary, all trials either not reporting or partially
reporting on a review benefit outcome were awarded High Risk (classifica-
tions A, D, E, and G in the ORBIT terminology), except for the outcome
seizure freedom for the Rosenfeld study, which was classified as Low Risk
(classifications B, C, F and H). The majority of trials not reporting on the
review harm outcomes were also classified as High Risk (classifications P1,
P2, R1, R2, R3, S1 and S2 in the ORBIT terminology) apart from five of
the harm outcomes in both the Yen and Zhang studies which were classi-
fied as Low Risk (classifications P3, T1, T2 and U). The trial report for the
Previtera study specifically mentioned that the outcome weight loss was not
measured (classification V), and hence is classified as No Risk in the final
column of Table 2. As explained in Section 3, the method developed in this
paper makes no distinction between No Risk and Low risk, and so for the
purposes of this analysis No Risk is simply coded as Low Risk.
3 Sensitivity analysis for benefits and harms
Our former paper [6] showed how ORBIT risk classifications for benefit out-
comes can form the basis for a general likelihood-based sensitivity analysis.
In this section we present a simpler version which is easier to use in practice,
and then show how the method can be extended to include harm outcomes.
3.1 Unadjusted estimates
The standard fixed effects model for outcome yi is
yi ∼ N(θ, σ2i ) , (1)
where θ is the (assumed constant) treatment effect and σi is the within-study
standard deviation. If we ignore the studies where the outcome of interest
is unreported, then the standard (unadjusted) fixed effects estimate of the
treatment effect is
θˆU =
∑
Repwiyi∑
Repwi
, (2)
where the suffix Rep on the summation signs means adding over all those
studies for which the value of yi is reported, and the weights wi are
wi = σ
−2
i .
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The corresponding (unadjusted) 100(1− α)% confidence limits are
{θˆU − zαsθ, θˆU + zαsθ} , (3)
where sθ is the standard deviation of θˆU given by
sθ = (
∑
Rep
wi)
− 1
2 ,
and zα = Φ
−1(1−α/2) is the appropriate standard normal percentage point
(e.g. z0.95 = 1.96). The usual (unadjusted) p-value for the null hypothesis
H0 : θ = 0 is
pU = P
χ2 ≥
(
θˆU
sθ
)2 , (4)
where χ2 denotes the chi-squared distribution on one degree of freedom.
These are standard calculations, but before showing how these can be
extended to bias-adjusted estimates it is worth pointing out that (2), (3)
and (4) can also be calculated through a likelihood-based approach. From
the fixed effects model (1), the (unadjusted) log-likelihood function for θ (the
sum of the log probabilities of what has been observed) simplifies to (omitting
irrelevant additive constants)
−1
2
∑
Rep
(yi − θ)2
σ2i
,
which in turn simplifies to
LU(θ) = −(θ − θˆU)
2
2s2θ
. (5)
The unadjusted estimate θˆU in (2) is the maximum likelihood estimate (MLE)
in the sense that it is the value of θ which maximizes LU(θ). The unadjusted
confidence interval (3) can also be obtained directly from LU(θ) by using
a standard asymptotic result in the theory of likelihood functions, that the
distribution of twice the log likelihood ratio for any single value of θ is (ap-
proximately) χ2 on one degree of freedom. This means that the confidence
limits in (3) are the two values of θ which satisfy the equation
LU(θ) = LU(θˆU)− 1
2
z2α . (6)
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Equivalently, they are the two values of θ which maximize
− {LU(θˆU)− LU(θ) + 1
2
z2α}2 . (7)
The unadjusted p-value (4) is
pU = P[χ
2 ≥ 2{LU(θˆU)− LU(0)}] . (8)
3.2 ORB-adjusted estimates for benefit outcomes
For each study with at least one unreported or partially reported benefit
outcome, we assume that either (i) the outcome was measured but failed to
show a significant treatment effect, or (ii) the outcome was not measured
or was unreported for reasons unconnected with the study results. Case (i)
will lead to a bias in the overall treatment effect estimate, but not in case
(ii). If case (i) is known to be true, the bias will be in the direction away
from the null, resulting in over-estimation of the treatment effect and exag-
geration of significance (p-value too small). Assuming that the ORBIT risk
assessment correctly identifies case (i) as High Risk (Table 1, last column),
explicit bias adjustments can be obtained by adding extra terms onto the
likelihood function (5) which take account of those studies with missing or
partially reported outcomes and High Risk ORBIT assessments.
From (1), the probability that the outcome yi is not significant (at the α
level) is
P(−zασi < yi < zασi) = Φ
{
zα − θ
σi
}
− Φ
{
−zα − θ
σi
}
, (9)
where Φ is the cumulative distribution function of the standard normal dis-
tribution. So if it is assumed that a High Risk ORBIT assessment correctly
identifies those studies which fall under case (i), then we can get a modi-
fied likelihood function by adding the log of (9) onto LU(θ) for each study
in which the benefit outcome is assigned a High Risk ORBIT classification.
The resulting log likelihood function for a benefit outcome is therefore
LB(θ) = −(θ − θˆU)
2
2s2θ
+
∑
High
log
[
Φ
{
zα − θ
σi
}
− Φ
{
−zα − θ
σi
}]
. (10)
The bias-adjusted estimate θˆB, the corresponding confidence interval and p-
value, can be obtained in exactly the same way as in Section 3.1 by using the
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log likelihood LB(θ) instead of LU(θ). So θˆB is the value of θ which maximizes
(10), maximizing the function analogous to (7) gives bias-adjusted confidence
limits, and the analogue of (8) gives the corresponding bias-adjusted p-value.
The second term in (10) adds more weight to values of θ close to zero, and
so, as expected, the bias-adjusted MLE from LB(θ) is always closer to the
null than the MLE from LU(θ).
Comparing these adjusted estimates and confidence intervals for benefit
outcomes with the corresponding unadjusted results in Section 3.1 gives a
relatively simple sensitivity analysis for assessing the robustness of conclu-
sions to outcome reporting bias. This has a different focus than the more
elaborate method proposed in [6], which is designed to show the sensitivity
of bias corrections for benefit outcomes on the reliability (ρ1) and specificity
(ρ2) of the ORB assessments. The adjustments proposed here take exactly
the same form as the unadjusted results and so the sensitivity analysis for
different benefit outcomes can be easily summarized in a table, whereas the
results of applying the method in [6] lead to a separate contour plot for each
benefit outcome showing how the bias corrections depends on the values of
ρ1 and ρ2. The two methods are formally equivalent when ρ1 = ρ2 = 1,
described in section 3.4 of [6] as the ‘special case of correct risk assessments’.
A further advantage of the current approach is that the method extends
directly to harm outcomes as shown in the next section.
3.3 ORB adjusted estimates for harm outcomes
As discussed in Section 1, ORBIT risk classifications for harm outcomes
focus on the possibility that researchers may concentrate on the positive
benefits of the experimental treatment and so be more likely to suppress
those harms outcomes which cast the new treatment in an unfavourable
light. If we assume that a positive value of the treatment effect for a harm
outcome indicates an increase in the incidence of a particular side effect, then
the corresponding ORB-adjustment method is very similar to the benefits
case except that we now identify a High Risk ORBIT assessment with those
unreported studies for which yi > 0 (treatment is actually harmful). These
are the studies shown as High Risk in the final column of Table 2.
From (1),
P(yi > 0) = Φ
(
θ
σi
)
, (11)
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and so the overall likelihood for a harm outcome is
LH(θ) = −(θ − θˆU)
2
2s2θ
+
∑
High
log
[
Φ
(
θ
σi
)]
. (12)
The ORB adjustment for a harm outcome follows from LH(θ) in exactly the
same way as before: the adjusted estimate θˆH maximizes LH(θ), and by re-
placing LU(θ) with LH(θ) in (7) and (8) we get the corresponding confidence
limits and p-value. The second term in (12) adds more weight to positive
values of θ, and so the bias-adjusted MLE from LH(θ) is usually larger and
further away from the null than the unadjusted MLE from LU(θ).
3.4 Calculating the bias adjustments for benefits and
harms
To fit the likelihood-based models of sections 3.2 and 3.3 we need the values
of yi and σ
2
i for each of the studies reporting the outcome of interest, and
estimates of σ2i for each of the studies not reporting the outcome and classified
as High Risk. Data for the reporting studies can be obtained directly from
the individual study results, but the values of σ2i for unreported outcomes
will not usually be available. We follow [6] by suggesting how these can be
imputed from data on the study sample sizes.
The quantities yi and σ
2
i for the studies reporting each outcome depend on
the statistical properties of the outcomes being measured. The most common
case, as in the example of Section 2, is when the studies are comparing the
incidence of a binary response, observing ai responses out of n1i patients in
the treatment group and ci responses out of n2i patients in the control group.
The raw data for the ith study are the four frequencies (ai, bi, ci, di), where
bi = n1i− ai and di = n2i− ci. Taking θ to be the log relative risk, yi and σ2i
are
yi = log
{
ain2i
cin1i
}
, (13)
and
σ2i =
n1i − ai
n1iai
+
n2i − ci
n2ici
. (14)
When a study observes one or more zero cells, we follow [8] by adding 0.5 to
all of the cells for that study, except when ai = ci = 0 or bi = di = 0 in which
case the study is omitted altogether (this occurred only twice amongst the
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12 × 14 outcome calculations in the epilepsy example). We have used the
zero-cell convention often used in Cochrane reviews, but a number of other
conventions have also been suggested.
If the total sample sizes ni = n1i + n2i are available (or estimated from
the study report) for all of the studies being considered, then it is possible
to impute the values of σ2i even for studies where the outcome of interest
is unreported. For most statistical problems, variances of estimates are, at
least approximately, inversely proportional to the sample size. This suggests
that
σ−2i ≈ kni
for some proportionality factor k. Following [6], the value of k can be esti-
mated from the data on the reporting studies by
kˆ =
∑
Rep σ
−2
i∑
Rep ni
. (15)
The value of σ2i for a High Risk study with sample size ni can then be imputed
as
σ2i ≈
1
kˆni
. (16)
3.5 ORB adjustments for the Topiramate example
Details of the Topiramate example have been set out in Section 2 above. The
meta analysis considered 12 studies and 14 outcomes (two benefit outcomes
and 12 harm outcomes). Table 3 shows which of these studies reports data
on these outcomes, and, for the studies with missing data, which of these
are rated as High Risk by the ORBIT assessment. The data take the form
discussed in Section 3.4, each reporting study measuring the incidence of
the appropriate binary response for the treatment and control groups. The
Cochrane review in [7] reports a detailed (unadjusted) meta analysis of these
studies. The raw data file which contains the sample sizes for each included
study and the number of events for each intervention and each review out-
come considered, can be found in Supplementary Table 1.
To implement the methods of Sections 3.1-3.3, the log relative risks yi
and standard errors σi for the reporting studies are calculated as in (13) and
(14). Values of σi for the missing studies are imputed using the formula in
(16). Table 4 shows the resulting unadjusted and ORB-adjusted relative risk
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estimates and confidence intervals for these data. Note that the figures shown
in the table are relative risks and not log relative risks, so a typical estimate
θˆ is displayed as exp(θˆ). For the value of α, we have followed the Cochrane
review by calculating 95% confidence intervals for benefit outcomes and 99%
confidence intervals for the harm outcomes. As expected, the ORB-adjusted
benefit treatment effects and confidence limits are smaller (closer to the null)
than the corresponding unadjusted values, whilst the harm estimates are all
larger (further from the null). Evidently, ignoring outcome reporting bias
tends to exaggerate the benefits of the treatment and underestimate the
severity of its side-effects.
There was little shift in the bias adjusted estimates for the review primary
benefit outcome (50% reduction in seizure frequency) because there was only
one study that was suspected of High Risk ORB for this outcome. When
considering seizure freedom (benefit outcome), where nearly half the included
studies did not report any useable data on this outcome, the bias adjusted
result suggested that the original unadjusted estimate was overestimating
treatment effect by more than 20%. Of the 12 harm outcomes, two with a
non-statistically significant result became significant after adjustment, and
for five of the harm outcomes (42%) the harmful effect of treatment was
underestimated by 10% or more.
3.6 Simulating the example
This section reports the results of a simulation study designed to assess the
statistical properties of these methods, with a particular focus on study char-
acteristics similar to those seen in the example of Section 3.5. This is essen-
tially a parametric bootstrap — we fit a model to the data of interest, take
the fitted model as if it was the true model, and then simulate a large num-
ber of times to assess the sampling properties of the resulting estimates and
confidence intervals. The results are summarized in Table 5.
The parameters for the simulation are provided by the analysis of section
3.5. For each of the 14 outcomes, the true value of the log relative risk θ is
taken to be the adjusted maximum likelihood estimate taken from Table 4,
and the study variances σ2i are taken to be the estimates calculated directly
from the study data or imputed using (16). This allows us to simulate values
of yi from (1). Making the ORB assumptions set out at the start of Section
3.2, we can then simulate the incidence of High risk and Low risk missing
studies in such a way that the expected numbers of Reported (R), High
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risk (H) and Low risk (L) studies match the numbers observed in the data
(the last three columns of Table 5). For each outcome, the Low risk studies
are randomly chosen from the complete set of 12 studies, and the High risk
studies are chosen at random from amongst those remaining studies which
have a non-significant value of yi (for a benefit outcome) or a positive value
of yi (for a harm outcome). The probabilities used in selecting these missing
studies are taken as the corresponding data proportions. For each simulation,
we can then calculate the unadjusted and adjusted estimates and confidence
intervals as in Sections 3.1-3.3. By including all 14 outcomes the simulations
cover a wide range of different rates of missing outcomes.
Table 5 shows the simulation estimates of three performance measures:
bias E(θˆ−θ), mean squared error E(θˆ−θ)2, and CI risk defined as P (θ /∈ CI),
or one minus the coverage of the confidence interval CI. The simulation
sample size of 10,000 ensures that the simulation standard error in these
figures is at most two units in the third decimal place. The bias of the
unadjusted estimates reflects outcome reporting bias: as expected the bias is
positive for the benefit outcomes and negative for the harm outcomes. The
bias of the adjusted estimates reflects asymmetry in the likelihood functions
(10) and (12), particularly noticeable if the number of high risk studies is
relatively large compared to the number of reported studies, as is the case
for some of the harm outcomes lower down in the table. However, for most of
the outcomes the adjusted estimates are, on average, closer to the true value
of θ than the unadjusted estimates, and in all cases the bias of the adjusted
estimate is more than offset by the improvement in variance. Mean squared
error (m.s.e. = variance + bias2) is usually taken as the best overall measure
of estimation accuracy: as seen in the table the adjusted estimates have lower
m.s.e. than the unadjusted estimates for all 14 of the outcomes. The quality
of a confidence interval CI is usually measured by its coverage, the actual
probability P (θ ∈ CI) that the true value of the parameter belongs to CI,
and by how much this differs from its nominal value, taken here to be 95%
for benefit outcomes and 99% for harm outcomes. Simulation estimates of
P (θ /∈ CI) = 1 − P (θ ∈ CI) are shown in the pair of columns headed ‘CI
risk’. In all but one of the outcomes, CI risk for the adjusted estimate is
smaller than for the unadjusted estimate, and the single difference the other
way round may just be the result of simulation error.
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4 Mantel-Haenszel estimates
4.1 ORB adjustments for Mantel-Haenszel estimates
Section 3 is based on maximum likelihood methods for estimating the treat-
ment effect parameter θ and formulating its ORB adjustments. Amongst
alternative approaches, Mantel-Haenszel methods [9] are sometimes used in
Cochrane reviews, including the published review of the Topiramate data
in [7]. This section suggests how the maximum likelihood approach can be
extended to cover Mantel-Haenszel (and other) estimates. The main change
is a reformulation of the definitions of θˆU and σ
2
θ given in Section 3.1. Section
4.2 illustrates Mantel-Haenszel ORB adjustments by a second re-analysis of
the Topiramate data.
If the missing outcomes are ignored, the Mantel-Haenszel estimate of the
unadjusted log relative risk is
θ˜U = log
(∑
Rep w˜i exp(yi)∑
Rep w˜i
)
, (17)
where the weights are now
w˜i =
cin1i
ni
.
The term exp(yi) in (17) is the relative risk for the ith study (formula (13)
without the log), and so the main difference between (17) and (2) is the
position of the log transformation: θ˜U is the log of a weighted average of the
relative risks, whereas θˆU is a weighted average of the logs of the relative risks.
This difference can be noticeable if study sample sizes are small especially
if some of the observed frequencies are relatively close to zero, but for large
sample sizes there is usually little difference between them.
Following the notation in [8], the variance of θ˜U is
s˜2θ =
P
RS
,
where
P =
n1in2i(ai + ci))− aicini
n2i
, R =
ain2i
ni
, S =
cin1i
ni
.
The corresponding 100(1− α)% Mantel-Haenszel confidence interval for θ is
{θ˜U − zαs˜θ, θ˜U + zαs˜θ} . (18)
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As before, (17) and (18), as well as its associated p-value
p˜U = P
χ2 ≥
(
θ˜U
s˜θ
)2 ,
can be calculated using the same likelihood approach as set out in Section 3.1,
but now applied to the Maentel-Haenszel version of the unadjusted (pseudo-)
likelihood
L˜U(θ) = −(θ − θ˜U)
2
2s˜2θ
.
The contribution of a High Risk study to the likelihood, the log of either (9)
for a benefit outcome or (11) for a harm outcome, depends only on the model
(1) and so is exactly the same as before. So the Mantel-Haenszel version of
the benefits likelihood is
L˜B(θ) = −(θ − θ˜U)
2
2s˜2θ
+
∑
High
log
[
Φ
{
zα − θ
σi
}
− Φ
{
−zα − θ
σi
}]
,
and similarly
L˜H(θ) = −(θ − θ˜U)
2
2s˜2θ
+
∑
High
log
[
Φ
(
θ
σi
)]
for a harm outcome. Maximizing these likelihoods gives the corresponding
ORB adjustment to the Mantel-Haenzsel estimate. The associated confidence
intervals and p-values also follow from the likelihoods as before.
4.2 Mantel-Haenzsel ORB adjustments for the Topi-
ramate meta analysis
Table 4, giving the results of applying the maximum likelihood methods
of Section 3 to the Topiramate example, is not exactly comparable to the
Cochrane review in [7] which was based on Mantel-Haenzsel methods. Table 6
shows the corresponding results using the theory of Section 4.1. As expected,
the unadjusted estimates in Table 6 now agree exactly with the published
review estimates in [7]. The Mantel-Haenzsel unadjusted relative risks are
all larger then the maximum likelihood estimates, although the differences
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are usually small with the possible exception of three of the harm outcomes
where the raw data show a relatively high incidence of zero cells in the control
group. The sizes of the bias adjustments shown in Table 6 are very similar
to the corresponding bias adjustments in Table 4, reflecting the fact that
the two versions of the likelihoods differ only in their unadjusted estimation
components, with exactly the same likelihood contributions from the High
Risk studies.
5 Random effects model
All of the methods developed so far have been based on the fixed effects
model (1). The model assumes homogeneity across the studies, in the sense
that all the treatment effects yi are estimating the same common parameter
θ. If the problem of ORB is ignored, then this would mean that the variation
between the observed outcomes yi would be adequately explained by the
within-study variances σ2i . The usual homogeneity test statistic for this is
Q =
∑
Rep
wi(yi − θˆU)2 . (19)
Under the fixed effects model, the value of Q would then have a χ2 distribu-
tion on (nRep − 1) degrees of freedom, where nRep is the number of studies
reporting the outcome of interest. This can be tested for each of the outcomes
being considered. In the Topimarate meta analysis, for example, all of the 14
values of Q turn out to be less than the 95th percentile of the appropriate χ2
distribution, suggesting that the fixed effects model is probably a reasonable
assumption in this case. However, some caution is needed when interpreting
the Q test in the presence of ORB. Arguably, if θ is reasonably small then for
benefit outcomes the presence of ORB is likely to mask some of the values
of yi close to the null, which may increase the observed scatter amongst the
reporting studies. The Q test (19) would then tend to be conservative. It is
not clear whether this would also hold for harm outcomes.
If the scatter of the observed yis is substantial, or if heterogeneity is
otherwise anticipated from the context of the studies, then the random effects
model
yi ∼ N(θ, σ2i + τ 2)
is usually the preferred alternative. There are now two unknown parameters,
θ as before, and τ 2, the random effects variance. The likelihood functions in
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Section 3 generalize to
LU(θ, τ
2) = −1
2
∑
Rep
{
log(σ2i + τ
2) +
(yi − θ)2
σ2i + τ
2
}
,
LB(θ, τ
2) = LU(θ, τ
2) +
∑
High
log
[
Φ
{
zασi − θ√
(σ2i + τ
2)
}
− Φ
{ −zασi − θ√
(σ2i + τ
2)
}]
,
and
LH(θ, τ
2) = LU(θ, τ
2) +
∑
High
log
{
Φ
(
θ√
(σ2i + τ
2)
)}
.
To estimate θ by maximum likelihood we now have to maximize these
likelihood functions over both parameters. Equivalently, we can do this in
two stages. First, maximize out τ 2 for each individual value of θ to give the
profile likelihood function for θ. For example, the unadjusted fixed effects
likelihood LU(θ) becomes
L
(P )
U (θ) = max
τ2
LU(θ, τ
2) ,
and similarly for the bias adjusted profile likelihoods L
(P )
B (θ) and L
(P )
H (θ).
The second stage is to find the values of θ which maximize these profile
likelihoods. The second stage also gives the asymptotic confidence limits
for θ. After replacing LU(θ) in (6), (7) and (8) by the appropriate profile
likelihood, we can follow exactly the same procedure as set out before in
Section 3. This likelihood approach to random effects models extends the
method of Hardy and Thompson in [10].
6 Discussion
The ORBIT methodology is gaining wide acceptance, particularly amongst
the Cochrane community of systematic reviewers, as the accepted approach
for studying ORB by re-examining studies (i) that might have been eligible
for inclusion in a review or meta analysis, but were subsequently not included
because they did not fully report on particular review outcomes of interest,
and (ii) that were included in relation to some, but not all, of the review
outcomes of interest. If outcome data are unavailable from trial authors then
review authors should assess the potential impact of ORB on their reviews
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and meta-analyses by using sensitivity analysis approaches. For benefit out-
comes a number of approaches for adjusting review meta-analyses for ORB
have been proposed ([11], [12]), although the method suggested in this ar-
ticle is the currently recommended approach by the ORBIT team, as this
model-based approach reflects directly the empirical finding that significant
outcomes are more likely to be reported than those that are found not to be
significant. No previous methodology existed for adjusting for ORB in a meta
analysis of a harm outcome, although evidence suggests that the incomplete
reporting of harm outcomes may be worse than benefit outcomes [13]. The
novel ORB bias adjustment approach presented in this paper maps the con-
cept identified in the ORBIT II study that biased reporting or non-reporting
of harms data results from study authors (intentionally or otherwise) masking
the harms profile of particular interventions in favour of the benefit results.
This method complements the theoretical framework already recommended
for benefit outcome adjustment. As the epilepsy example shows, ORB can
effect the statistical conclusions to review meta analyses and also has the po-
tential to effect the clinical interpretations of treatment indications in both
benefit and harm outcomes.
ORB as a missing data problem.
Like all missing data problems, statistical analysis is impossible unless we
make assumptions about the missing data mechanism. The usual approach
in section 3.1 ignores ORB altogether, tacitly assuming that the missing out-
comes are missing at random [14]. This assumption is equivalent to a Low
Risk assessment under the ORBIT methodology, contradicting the High Risk
assessments found for many of the missing outcomes in the epilepsy example.
Our method makes the more plausible assumption that, for High Risk ben-
efit outcomes, the actual (or potential) values of yi, had they been reported,
would not be significantly different from the null and so lie somewhere in the
interval (9). For a High Risk harm outcome, our assumption is that the un-
observed yi would be somewhere in the interval (0,∞). These assumptions
give an explicit selection model for the general missing data methodology
introduced in [15] and reviewed in [14]. The interval structure of these as-
sumptions means that ORB is an example of censored data, although quite
different from the more usual censored life-time applications. If we think of
(1) as a parametric survival model, the harms likelihood (12) is similar to
the standard likelihood for right-censored data, the first term corresponding
to the fully observed outcomes and the second term corresponding to data
censored at the value y = 0. The second term in the benefits likelihood (10)
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corresponds to interval censoring using (9).
Seen in this light, the sensitivity analysis suggested in this paper is a
comparison between two missing data assumptions, that data are missing at
random (the unadjusted approach) or that the missing studies rated as High
risk correctly identify those unobserved estimates which are non-significant or
positive (the adjusted approach). The question is not whether the adjustment
assumptions are known to be correct, but whether the contrast between the
resulting estimates gives a useful indication of sensitivity to ORB. We are
comparing a statistically naive assumption (missing at random) with a more
plausible assumption guided by the systematic re-appraisal of the individual
research studies offered by the ORBIT methodology.
Statistical assumptions.
As well as these missing data assumptions, the example also relies on
other important assumptions. We have taken the study treatment effects yi
to be log relative risk, although, arguably, log odds ratios could also have
been used. The Cochrane guide [8] gives a useful summary of the treatment
effect measures most often used in clinical trails, and how to calculate their
variances. Note that the use of log transformations on relative risks and
odds ratios is a technical device to improve normal approximations and so
is not an assumption in the same sense. For example, the theory of Section
3 is based on log relative risks, but the numerical results in Tables 4 and 6
are transformed back to actual relative risks. Although normal approxima-
tions are almost always used in practice, the theory of Section 3 can also
be extended to non-normal distributions. The first term in the likelihoods
LB(θ) and LH(θ) remain as before, with θˆU and s
2
θ now being the appropri-
ate maximum likelihood estimate and variance using the reported data. The
quantities within the square brackets in the second terms of these likelihoods,
however, need to be replaced by the appropriate probability calculations cor-
responding to (9) and (11). Another important assumption is the fixed effects
model (1), as used in the original published Cochrane review of the epilepsy
studies. Section 5 shows how these ORB adjustments can also be used for
random effects models. The imputation of the missing variances using (16)
is a further assumption. However, trying alternative version of this formula
suggests that the adjusted estimates are reasonably robust: for example, the
statistical conclusions in terms of the significance or non-significance of the
adjusted estimates indicated in Table 4 continue to hold even if the imputed
missing outcome variances are scaled up or down by a factor of two.
Application of the ORB sensitivity analysis.
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In this paper the principal aim is to present the new methodology with an
application. There is clearly a separate discussion with regards to a) when
the adjustment should be applied, and to which outcomes, and b) whether
the adjusted estimates make a difference clinically. Both these decisions are
largely at the discretion of the clinical expert and may differ depending on the
application. Our recommendation is that the adjusted estimates are always
presented alongside the unadjusted estimated, as illustrated in Tables 4 and
6, such that the robustness of the conclusions to outcome reporting bias can
be assessed.
Implementing the ORB adjustments suggested in this paper involve the
maximization of likelihood functions and associated functions such as (7).
These are relatively easy to calculate using a general maximization routine
such as nlminb in R (or Splus), as we have used to obtain the results in
Tables 4, 5 and 6. Similar facilities are routinely available in other software
packages. The method extends easily to random effects models as described
in Section 5, since the profile likelihood step described in that section can also
be achieved using the same maximization routine. A web-based application
is being developed which will enable users to easily implement these methods
(http://www.outcome-reporting-bias.org/).
The correct application of the statistical adjustment method for outcome
reporting bias presented in this paper relies on a formal assessment of the
risk bias of missing study outcome data using ORBIT methodologies which
were published in the BMJ. To date, the risk of bias assessments have only
been validated for use in randomised controlled trials for benefit outcomes,
and applied in only a handful of non-randomised reports for harm outcomes
([3], [4], [5]). The application of the adjustment method to non-randomised
studies is therefore beyond the scope of this current research.
Supplementary material
Supplementary Table 1 gives the raw data for the Topiramate example, pre-
sented in the form of an input file for the web application referred to at the
end of Section 6. The first three rows of the table indicate, respectively,
outcome type (benefit or harm), percentage for the confidence intervals (95
or 99), and outcome title. Subsequent rows correspond to the 12 studies in
the order given in Table 3. In the body of Supplementary Table 1, the first
two columns give the sample sizes (n1i, n2i). The subsequent columns are
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arranged in pairs, giving the observed study frequencies (ai, ci) for each out-
come. A blank in these columns indicates that the outcome was not reported
(or only partially reported), in which case the High/Low ORBIT assessment
is indicated.
Supplementary Table 2 gives the detailed classification tables for each of
the studies in the Topiramate review, providing justification for the ORBIT
assessments.
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